Lonza’s Underperformance Spurs Swiss Market Decline – What Investors Must Watch
Lonza Group AG–REG’s underperformance in the Swiss market reflects declining margins, rising regulatory costs, and fierce competition—yet niche biopharma expansion and strategic partnerships offer potential upside.
4 minutes to read